VivoSeq
Gastroenterology

Chronic Pancreatitis

45

Pipeline Programs↗

13

Active Trials↗

24

Companies Involved↗

Chronic Pancreatitis is a moderately active landscape with 45 programs across 24 companies. The most active players are UCB, Jiangsu Topcel-KH Pharmaceutical Co., Ltd., Aimmune Therapeutics, Inc.. 3 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

66/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1A

Aimmune Therapeutics, Inc.

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

46 of 50 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody24%Protein / enzyme12%Cell therapy12%

Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 98% of 52 pipeline programs.

Analysis

Trial Status

46

clinical trials

Completed21 · 46%
Recruiting10 · 22%
Terminated8 · 17%
Active, not recruiting3 · 7%
Withdrawn3 · 7%
Unknown status1 · 2%

Clinical Trials

Trial Activity

46 trials

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Recruiting·IIndiana University·Phase 1·NCT05603702·24 enrolled
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
Recruiting·MMayo Clinic·Phase 2·NCT06729996·40 enrolled
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Recruiting·—·Phase 1·NCT05771675·90 enrolled
A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis
Recruiting·SShanghai Changzheng Hospital·Phase 1·NCT07314489·80 enrolled
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
Recruiting·—·Phase 1·NCT05664880·24 enrolled
Tocilizumab for Painful Chronic Pancreatitis
Recruiting·—·Phase 2·NCT06426160·36 enrolled
Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis
Recruiting·VVA Office of Research and Development·Phase 1·NCT05925036·40 enrolled
Metformin in Post Chronic Pancreatitis Diabetes Mellitus
Recruiting·—·Phase 4·NCT06937294·58 enrolled
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
Recruiting·MMedical University of South Carolina·Phase 1·NCT06205342·48 enrolled
Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis
Recruiting·—·N/A·NCT07074379·126 enrolled
An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Active, not recruiting·—·N/A·NCT05764629·324 enrolled
Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.
Active, not recruiting·—·N/A·NCT07022327·1 enrolled
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
Active, not recruiting·GGeorgetown University·Phase 1/2·NCT05551858·32 enrolled
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
Completed·RRadboud University Medical Center·Phase 2·NCT01551511·29 enrolled
Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Completed·UUniversity of Michigan·Phase 2·NCT00782795·64 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)